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The T790M mutation in EGFR accounts for approximately half of all lung cancer cases with acquired resis-
tance to the current clinical EGFR tyrosine kinase inhibitors. In tyrosine kinase inhibitor-resistant lung tumors,
rociletinib and AZD9291 are highly active when T790M is present andmodestly active when T790M is absent.The advent of targeted therapies has
transformed the treatment of several
types of cancer. However, the efficacy of
these drugs is thwarted by the inevitable
emergence of acquired resistance. In
lung cancers, epidermal growth factor
receptor (EGFR) mutations confer sensi-
tivity to EGFR tyrosine kinase inhibitors
(TKIs); however, disease progression
almost invariably occurs 1 year after
starting treatment (Figure 1). The most
prominent mechanism of acquired resis-
tance is the secondary EGFR mutation,
EGFRT790M, which is observed in 50%–
60% of resistant tumors.
The development of effective strategies
to treatTKI-resistant lung tumors is amajor
clinical need, and efforts have focused on
targeting EGFRT790M, given its high fre-
quency. Although the irreversible EGFR
inhibitor afatinib can inhibit EGFRT790M
in vitro, its use in patients is limited by
skin and gastrointestinal toxicities at the
doses required to achieve inhibition of
EGFRT790M. Interestingly, the combination
of afatinib with the monoclonal anti-EGFR
antibody cetuximab has demonstrated
activity against both EGFRT790M-positive
and EGFRT790M-negative resistant tumors
(Janjigian et al., 2014).
More recently, the third generation
mutant-selective EGFR inhibitors like
AZD9291 and rociletinib (CO-1686) have
emerged as potential therapeutics to
block the growth of EGFRT790M-positive
tumors (Cross et al., 2014; Walter et al.,
2013). These drugs have potent activity
against both the common EGFR muta-
tions (exon 19 deletions and the L858R
mutation) that confer sensitivity to EGFR
TKIs and the T790Mmutation that confersresistance. Most importantly, unlike the
first (erlotinib and gefitinib) and second
generation (afatinib) EGFR TKIs, both
AZD9291 and rociletinib have a signifi-
cantly increased potency for EGFR
mutants (including T790M) than for wild-
type (WT) EGFR. For patients, this has
the potential to translate into reduced
skin and gastrointestinal toxicities related
to inhibition of wild-type EGFR.
Two recent papers describe the results
of the early phase clinical trials of
AZD9291 and rociletinib in patients with
EGFR mutant lung cancer previously
treated with an EGFR inhibitor (Ja¨nne
et al., 2015; Sequist et al., 2015). Both
agents exhibited remarkable efficacy in
EGFRT790M-positive tumors, with 61%
and 59% response rates observed with
AZD9291 and rociletinib, respectively.
The progression-free survival (PFS)
observed in these patients was 9.6
(AZD9291) and 13.1 (rociletinib) months.
These represent significant improvements
over the combination of afatinib plus
cetuximab—the most promising regimen
to date for this patient population—
which showed a 32% response rate
and 4.8 month PFS in patients with
EGFRT790M-positive tumors (Janjigian
et al., 2014). Not surprisingly, the efficacy
of AZD9291 and rociletinib was lower in
EGFRT790M-negative tumors, where the
response rates were 21% for AZD9291
(median PFS 2.8 months) and 29% for
rociletinib (medianPFS5.6months). Over-
all, the data highlight the clear benefit
of using either of these inhibitors in
patients with EGFRT790M-positive disease
and potentially for some patients with
EGFRT790M-negative disease. These dataCancer Cewere generated in patients with disease
progression on prior TKIs, and it is un-
known how these agents would do if given
to treatment-naive patients.
As predicted from their selective activ-
ity against EGFR mutants, limited skin
and gastrointestinal toxicities were ob-
served in patients treated with AZD9291
or rociletinib. Interestingly, grade 3 hyper-
glycemia was seen in 22% of patients
treated with therapeutic doses of rocileti-
nib. This is potentially a consequence
of inhibition of insulin-like growth factor
receptor 1 (IGF1R) and the insulin recep-
tor by a metabolite of rociletinib. Because
IGF1R has been implicated in contri-
buting to resistance to EGFR TKIs, it will
be interesting to determine whether
inhibition of this receptor plays a role in
the efficacy of rociletinib. Hyperglycemia
was effectively managed with oral hypo-
glycemic agents like metformin, which
raises the question of whether these
agents also contribute anti-tumor effects
(Wheaton et al., 2014).
These encouraging results raise
important questions about optimizing
the use of these agents. First, do third
generation TKIs provide the most benefit
when used in patients with disease
progression following the use of a first or
second generation TKI or when used
as first-line therapy in the TKI-naive
setting? Head-to-head comparisons of
rociletinib (NCT02186301) or AZD9291
(NCT02296125) versus first generation
TKIs in untreated patients with EGFR
mutant lung cancer are currently ongoing.
Second, can the potential reduced
toxicity of third generation EGFR TKIs
be leveraged for combinations with otherll 27, June 8, 2015 ª2015 Elsevier Inc. 751
Figure 1. Schematic Representation of Potential Treatment Scenarios for Patients with EGFR Mutant Lung Adenocarcinomas
Initial treatment of TKI-naive patients with first or second generation TKIs elicits responses in most cases, followed by the inevitable acquisition of drug resistance
on average within a year. In 60% of cases, acquired resistance is accompanied by the emergence of the T790M mutation. Mechanisms of resistance in T790M-
negative tumors includeMET and HER2 amplification, phenotypic changes like epithelial mesenchymal transition (EMT) and the transformation to small cell lung
cancer (SCLC), and point mutations in BRAF and PIK3CA. When TKI-resistant tumors are treated with third generation TKIs, EGFRT790M-positive tumors show
the highest response rates. Resistance to third generation TKIs also develops, and emerging evidence suggests that, in some cases, tumors may acquire an
additional mutation in EGFR, C797S. Additionally, tumors may also lose the T790M mutation. Examples of possible combinations of EGFR mutations in tumors
resistant to third generation TKIs are shown.
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Previewstargeted agents? It is well-established
that resistance to EGFR TKIs can occur
via activation of pathways, like MET, that
bypass EGFR to signal downstream. Add-
ing agents to target these bypass mecha-
nisms could potentially further improve
the efficacy of third generation TKIs
and counter heterogeneous mechanisms
of resistance that can be present in indi-
vidual patients. In the TATTON trial
(NCT02143466), for example, the safety
and tolerability of AZD9291 in combina-
tion with AZD6094 (MET inhibitor), selu-
metinib (MEK inhibitor), and the immune
checkpoint inhibitor MEDI4736 are being
investigated.752 Cancer Cell 27, June 8, 2015 ª2015 ElseDespite the positive results, acquired
resistance to AZD9291 and rociletinib
also emerges (Piotrowska et al., 2015;
Thress et al., 2015). Analysis of circulating
free DNA derived from T790M+ patients
with acquired resistance to AZD9291 re-
vealed the presence of a novel EGFRC797S
mutation in roughly one-third of cases
examined. Because AZD9291 covalently
binds C797, this mutation likely prevents
drug binding. Cell line studies have vali-
dated that the EGFRC797S mutation does
confer resistance to the third generation
inhibitors (Ercan et al., 2015; Niederst
et al., 2015; Thress et al., 2015). The data
suggest that whether EGFRC797S occursvier Inc.in cis- or in trans- with EGFRT790M could
have profound consequences for the
drug sensitivity of the tumor cells
(Niederst et al., 2015). When EGFRT790M
and EGFRC797S are in cis, cells are resis-
tant to all EGFR TKIs, but, if they are
in trans, the cells are sensitive to the
combination of first and third generation
EGFR TKIs. Another layer of complexity
occurs when EGFRC797S is present in
the EGFRT790M-negative setting, where
cell line studies indicate that these
cells are resistant to third generation inhib-
itors but sensitive to first/second genera-
tion drugs (Ercan et al., 2015; Niederst
et al., 2015). To date, the EGFRC797S
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Previewsmutation has not been found in patients
treated with rociletinib (Piotrowska et al.,
2015). Further studies will be needed to
elucidate whether this reflects a bona
fide difference between AZD9291 and
rociletinib.
One third to half of EGFRT790M positive
tumors that acquire resistance to
AZD9291 or rociletinib lose the T790M
mutation (Piotrowska et al., 2015; Thress
et al., 2015). This is likely due to heteroge-
neity in the original tumor that becomes
apparent upon treatment with these
agents. The mechanisms of resistance in
most of these EGFRT790M-negative,
EGFRC797S-negative resistant clones
remain to be determined, but it is inter-
esting to note that a subset of these
tumors were found to have transformed
to small cell lung cancer (Piotrowska
et al., 2015). This phenotypic switch is
observed in a subset of EGFR mutant
tumors following treatment with first
generation TKIs, and it will be important
to determine whether the frequency of
this and other uncommon mechanisms
of resistance increases following treat-
ment with third generation inhibitors.AZD9291 and rociletinib represent an
important step forward in the treatment
of patients with EGFRT790M-positive lung
cancer. These drugs are likely to extend
the survival of patients with EGFR mutant
lung cancer and almost certainly will do
so with a better toxicity profile than previ-
ous therapies. The success of these
agents highlights the value of identifying
processes that underlie resistance to
targeted therapies to design mecha-
nism-based precision cancer therapies.
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